Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Caisse des Depots and Sanofi Sign an Agreement

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Agreement with Sanofi to help with Biocitech’s development.

The Caisse des Depots have signed an agreement with Sanofi to cover the Caisse des Depots buy-back of Biocitech, the technology park dedicated to life sciences.

Biocitech is a key element in the development of the biotechnology sector in the Seine-Saint-Denis department and in the Ile de France region. Sanofi was represented by general secretary Philippe Peyre.

Jean-Pierre Jouyet, general manager and Stephane Keita, territorial and network development manager represented the Caisse des Depots.

Claude Bartolone, president of the French National Assembly and representative for the Seine-Saint-Denis department attended today’s official signing. He was joined by Corinne Valls, vice-president of the Seine-Saint-Denis departmental council and Mayor of Romainville and Stephane Troussel, president of the Seine-Saint-Denis departmental council.

Gerard Cosme, president of the Est Ensemble metropolitan area also attended the ceremony with the Biocitech SAS president, Jean-Francois Boussard.

In 2002, Sanofi decided to launch an industrialization operation in partnership with the local authorities. Biocitech was fully established in 2003 and demonstrates Sanofi’s commitment to rehabilitate the area. The biotechnology and life sciences park currently hosts 25 companies, which employ around 350 people in Romainville.

The technology park is also a key element in the Medicen Paris Region network, the Greater Paris region’s world-class competitiveness hub for health and new therapies. Biocitech provides a range of specific services for firms operating within biotechnology, biopharmaceuticals, fine chemicals, medical and in vitro diagnostics and medical devices.

Today’s agreement has been established in collaboration with local authorities and the Ile de France institutions. Their aim is to develop the technology park. A new company, Biocitech Immobilier, will own it. The Caisse des Depots will retain an initial 40 per cent share.

They will acquire the remaining 60 per cent of the shares after further redevelopment is complete in the Galien building. Galapagos, one of the resident companies, will move into the Galien building in 2015.

Additionally, a portion of the site, representing 3.4 hectares (9.21 acres) will be rehabilitated and reorganized, in order to promote the economic development of the area. The objective is to turn Biocitech into an open campus. The firms installed at Biocitech will complement one another and generate strong synergies and collaborations.

Some key features at Biocitech:

• A unique blend of real estate and industrial expertise
• A service for young and thriving innovative companies
• A tailored offer for biotechnology SMEs, for activities such as imaging, medical devices, diagnostics and environment
• An active and long-lasting ecosystem, based on the residents’ commitment

This agreement is the start of a new growth dynamic. It is supported by an investment plan to optimize and rationalize the buildings.

All the partners will get together in order to have the residents stay as long as possible and to attract new tenants, while adding value to the real estate reserve.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

2012 in Review: Biocitech Focuses on Collaboration with Regional Players
In 2012, the technology park in Paris, France signed cooperation agreements with the Paris public hospital system, France's development research institute and the Paris Chamber of Commerce to provide tenant businesses with tools for development.
Tuesday, May 14, 2013
PupPharma Moves into the Biocitech Science Park
PupPharma is a CRO specialized in perinatal and pediatric pharmacology.
Friday, June 24, 2011
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!